Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Telomir Pharmaceuticals, Inc. (TELO)

Telomir Pharmaceuticals reports Ohio State osteosarcoma cell study results for Telomir-Zn

Neutral Impact 2 of 5 product/contract Written later

Telomir Pharmaceuticals announced preclinical research from The Ohio State University showing Telomir-Zn inhibited cell growth in human and canine osteosarcoma cell lines at similar low drug concentrations. The company said it is assessing a possible canine in vivo study while its triple-negative breast cancer program advances toward site initiation and Phase 1/2 enrollment. The filing reports no financial results, and the findings are preclinical.

Key points

  • Study tested Telomir-Zn on three cell lines: HOS (human), D17 (canine), and Abrams (canine).
  • All three osteosarcoma cell lines showed growth inhibition at similar low drug concentrations.
  • The company is in discussions with Ohio State and is assessing next steps for a potential canine in vivo efficacy study.
  • The TNBC program remains the immediate clinical focus, with an active IND cleared by the FDA.

The filing

CompanyTelomir Pharmaceuticals, Inc. (TELO)
Form8-K, current report
Filed with the SECSep 14, 2026, 8:00 AM ET
Accession number0001493152-26-042483

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.